Biofrontera faces a precarious path to profitability as its inconsistent revenue growth, which fluctuated between a 22.5% contraction and 36.2% expansion in recent quarters, fails to cover high commercialization costs. While gross margins have improved to 81.8...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.05+52.4% vs -$0.10 | $12M+26.3% vs $10M |
Q2 2026 May 14, 2026 | -$0.41-256.5% vs -$0.12 | $10M-1.6% vs $10M |
Q2 2026 Mar 19, 2026 | $0.50+72.4% vs $0.29 | $17M+5.9% vs $16M |
Q4 2025 Nov 12, 2025 | -$0.59+1.7% vs -$0.60 | $7M-56.7% vs $16M |
Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera's photodynamic therapy platform
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.
WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.
Benchmark BFRI against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Biofrontera Inc. (BFRI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.15 | $14.72M | -1.28 | 11.8% | -25.26% | -141.3% | — | |
| $6.50 | $178.89M | -13.83 | 10.2% | -8.95% | -20.23% | — | |
| $13.84 | $1.92B | -1.35 | -2.75% | -41.85% | -55.97% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $3.32 | $1.15B | 38.92 | 0.57% | 2.07% | 2.61% | — | |
| $0.68 | $87.7M | -4.23 | -10.02% | -9.79% | -47.84% | — |
Biofrontera Inc. (BFRI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Biofrontera Inc. (BFRI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jun 17, 2026·SEC
May 14, 2026·SEC
Get notified when BFRI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Biofrontera Inc. (BFRI) stock FAQ — growth, dividends, profitability & financials explained
Biofrontera Inc. (BFRI) reported $46.2M in revenue for fiscal year 2025. This represents a 76% increase from $26.2M in 2019.
Biofrontera Inc. (BFRI) grew revenue by 11.8% over the past year. This is steady growth.
Biofrontera Inc. (BFRI) reported a net loss of $6.4M for fiscal year 2025.
Biofrontera Inc. (BFRI) has a return on equity (ROE) of -141.3%. Negative ROE indicates the company is unprofitable.
Biofrontera Inc. (BFRI) had negative free cash flow of $7.9M in fiscal year 2025, likely due to heavy capital investments.
